Atazanavir

This classification denotes a protease inhibitor with the molecular formula C38H52N6O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QZU4H47A3S, chemically known as 2,5,6,10,13-pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-, dimethyl ester, (3s,8s,9s,12s)- but generally known as atazanavir, which bears US NIH Compound Identifier 148192. Atazanavir most often comes in base and sulfate forms. European Medicines Agency schedules Atazanavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16398MIG. The term ATAZANAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, No. 4, 2003, List 50). World Health Organization schedules atazanavir in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule atazanavir under HS 29333999 and SITC 51574. As of Q4 2014, ATAZANAVIR remains the US FDA Preferred Term for this commodity. Atazanavir bears US NLM identifiers UMLS ID C1145759 and NCI Concept Code C66872. SMILES: OC(C(NC(=O)C(NC(=O)OC)C(C)(C)C)Cc1ccccc1)CN(NC(=O)C(NC(=O)OC)C(C)(C)C)Cc1ccc(cc1)c1ncccc1.